DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,008,939 B2 Christoph (45) Date of Patent: Mar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,008,939 B2 Christoph (45) Date of Patent: Mar USOO70O8939B2 (12) United States Patent (10) Patent No.: US 7,008,939 B2 Christoph (45) Date of Patent: Mar. 7, 2006 (54) USE OF WEAK OPIOIDS AND MIXED WO WO 93/15062 8/1993 OPIOIDAGONISTS/ANTAGONISTS FOR WO WO 98/46216 10/1998 TREATMENT OF URINARY INCONTINENCE WO WO 99/22737 5/1999 (75) Inventor: Thomas Christoph, Aachen (DE) OTHER PUBLICATIONS Dray et al., “Meptazinol: Unusual In Vivo Opioid Receptor (73) Assignee: Gruenenthal GmbH, Aachen (DE) Activity at Supraspinal and Spinal Sites”, Neuropharmacol ogy, vol. 25, No. 4 (1986), pp. 343-349. (*) Notice: Subject to any disclaimer, the term of this JP 07053534 A, Patent Abstracts of Japan, no date available. patent is extended or adjusted under 35 Parfitt, Martindale-The Complete Drug Reference- Thirty U.S.C. 154(b) by 0 days. Second Edition, Pharmaceutical Press, 1999, pp. 26-29, 34, 52-53, and 89. (21) Appl. No.: 10/448,322 Murray, “Acute Urinary Retention Associated with Sublingual Buprenorphine”, British Medical Journal, vol. (22) Filed: May 30, 2003 286, No. 6367 (1983), pp. 763-764. Malinovsky et al., “The Urodynamic Effects of Intravenous (65) Prior Publication Data Opioids and Ketoprofen in Humans', Anesthesia and US 2004/0029905 A1 Feb. 12, 2004 Analgesia, vol. 87, No. 2 (1998), pp. 456-461. Fowler et al., “Effects of Liquid Diphenoxylate Related U.S. Application Data Hydrochloride and Atropine Sulfate (Lomotil). Instillations on Dynamics and Function of Continent Cecal Urinary (63) Continuation of application No. PCT/EP01/13911, Reservoirs”, The Journal of Urology, vol. 138, No. 4 (1987), filed on Nov. 28, 2001. pp. 735-738. Aceto et al., “Stereoselective Mu- and Delta-Opioid Recep (30) Foreign Application Priority Data tor-Related Antinociception and Binding with (+)- Nov. 30, 2000 (DE) ................................ 1OO 59 415 Thebaine” (Abstract), PubMed Database, National Library of Medicine, no date available. (51) Int. Cl. Speigel et al., “Meptazinola Novel Mu-1 Selective Opioid A6 IK3I/55 (2006.01) Analgesic’ (Abstract), Biosis Database, no date available. A6 IK3I/44 (2006.01) Elwood, “Sticky Business: Patterns of Procurement and A6 IK3I/24 (2006.01) Misuse of Prescription Cough Syrup in Houston”, Journal of (52) U.S. Cl. .................. 514/212.01; 514/282; 514/538 Psychoactive Drugs, vol. 33, No. 2 (2001), pp. 121-133. (58) Field of Classification Search ........... 514/212.01, 514/282, 538 * cited by examiner See application file for complete Search history. Primary Examiner-Raymond J. Henley, III (74) Attorney, Agent, or Firm-Crowell & Moring LLP (56) References Cited U.S. PATENT DOCUMENTS (57) ABSTRACT 5,354,863 A 10/1994 Dappen et al. A pharmaceutical composition for the treatment of an 5,840,696. A 11/1998 Lippton increased urge to urinate or urinary incontinence, compris 5,859,043 A 1/1999 Kapusta ing an effective amount of at least a compound Selected from RE36,547 E * 2/2000 Crain et al. ................. 514/282 the group consisting of codeine, dihydrocodeine, dextropro 6,159,501 A * 12/2000 Skinho...................... 424/461 poxyphene, meptazinol and tilidine. Also disclosed are 2003/O166670 A1 9/2003 Brooks-Korn .............. 514/282 methods of treatment using the pharmaceutical composi FOREIGN PATENT DOCUMENTS tions and preferred dosages for the treatment methods. DE 1994.7747 4/2001 EP O913152 5/1999 17 Claims, No Drawings US 7,008,939 B2 1 2 USE OF WEAK OPODS AND MIXED propiverine or tolterodine, tricyclic antidepressants, Such as OPIOID AGONISTS/ANTAGONISTS FOR imipramine, or muscle relaxants, Such as flavoxate. Other TREATMENT OF URINARY INCONTINENCE medicaments, which in particular increase the resistance of the urethra or of the neck of the bladder, show affinities for CROSS REFERENCE TO RELATED C.-adrenoreceptors, Such as ephedrine, for B-adrenorecep APPLICATIONS tors, Such as clenbutarol, or are hormones, Such as oestra diol. The present application is a continuation of International Certain diarylmethylpiperazines and -piperidines are also Patent Application No. PCT/EP01/13911, filed Nov. 28, described for this indication in WO 93/15062. For tramadol 2001, designating the United States of America and pub also a positive effect on bladder function has been demon lished in German as WO 02/43713 A2, the entire disclosure Strated in a rat model of rhythmic bladder contractions of which is incorporated herein by reference. Priority is (Nippon-Shinyaku, WO 98/46216). The literature further claimed based on Federal Republic of Germany Patent more contains Studies on characterization of the opioid Side Application No. 10059 415.8, filed Nov. 30, 2000. effect of urine retention, which give Some indications of the 15 influence on bladder functions by weak opioids, Such as FIELD OF THE INVENTION diphenoxylate (Fowler et al., 1987.J. Urol 138:735–738) and meperidine (Doyle and Briscoe, 1976 Br J Urol The invention relates to the use of weak opioids and 48:329-335), by mixed opioid agonists/antagonists, Such as mixed opioid agonists/antagonists for the preparation of a buprenorphine (Malinovsky et al., 1998 Anesth Analg medicament for the treatment of an increased urge to urinate 87:456-461; Drenger and Magora, 1989 Anesth Analg or urinary incontinence, and to corresponding medicaments 69:348-353), pentazocine (Shimizu et al. (2000) Br. J. and methods for treatment of an increased urge to urinate or Pharmacol. 131 (3):610-616) and nalbuphine (Malinovsky urinary incontinence. et al., 1998, loc. cit.), and by potent opioids, Such as morphine (Malinovsky et al., 1998 loc. cit.; Kontani and BACKGROUND OF THE INVENTION 25 Kawabata, (1988); Jpn J Pharmacol. Sep;48(1):31) and fentanyl (Malinovsky et al., 1998 loc. cit.). However, these Urinary incontinence is the involuntary discharge of Studies were usually conducted in analgesically active con urine. This occurs in an uncontrolled manner when the centrations. preSSure within the urinary bladder exceeds the pressure In the case of the indications in question here, however, it needed to close the ureter. Causes can be on the one hand an should be remembered that it is in general a matter of very increased internal pressure in the bladder (e.g. due to detru long-term uses of medicaments and, in contrast to many sor instability) with the consequence of urgency inconti Situations where analgesics are employed, those affected are nence and on the other hand a reduced Sphincter preSSure faced with a situation which is very unpleasant but not (e.g. following giving birth or Surgical interventions) with intolerable. It is therefore to be ensured here-even more so the consequence of StreSS incontinence. The detrusor is the 35 than with analgesics-that Side effects are avoided if the coarsely bundled multilayered bladder wall musculature, perSon affected does not want to exchange one evil for contraction of which leads to discharge of urine, and the another. Also, analgesic actions are also largely undesirable Sphincter is the closing muscle of the urethra. Mixed forms during permanent treatment of urinary incontinence. of these types of incontinence and So-called overflow incon tinence (e.g. in cases of benign prostate hyperplasia) or 40 DESCRIPTION OF THE INVENTION reflex incontinence (e.g. following damage to the spinal cord) occur. Further details in this respect are to be found in The object of the present invention was therefore to Chutka, D. S. and Takahashi, P. Y., 1998, drugs 560: discover Substances which are helpful for treatment of an 587-595. increased urge to urinate or urinary incontinence and at The urge to urinate is the State, aimed at discharge of urine 45 active doses preferably Simultaneously show fewer Side (miction), of increased bladder muscle tension as the bladder effects and/or analgesic actions. capacity is approached (or exceeded). This tensioning acts Surprisingly, it has now been found that certain weak here as a Stimulus to miction. An increased urge to urinate opioids and mixed opioid agonists/antagonists have an out is understood here as meaning in particular the occurrence of Standing action on bladder function at low concentrations a premature or increased and Sometimes even painful urge to 50 and accordingly are particularly Suitable for treatment of urinate up to So-called Strangury. This consequently leads to corresponding diseases. Significantly more frequent miction. Causes can be, inter The invention accordingly provides the use of one of the alia, inflammations of the urinary bladder and neurogenic following compounds bladder disorders, and bladder tuberculosis. However, all codeine or dihydrocodeine, causes have not yet been clarified. 55 dextropropoxyphene, An increased urge to urinate and urinary incontinence are meptazinol or extremely unpleasant and there is a clear need among perSons afflicted by these conditions to achieve an improve tilidine ment which is as long-term as possible. as free base and/or in the form of physiologically acceptable An increased urge to urinate and in particular urinary 60 Salts for the preparation of a medicament for treatment of an incontinence are conventionally treated with medicaments increased urge to urinate or urinary incontinence. using Substances which are involved in the reflexes of the Surprisingly, it has been found that these compounds lower urinary tract (Wein, A. J., 1998, Urology 51 (suppl. Significantly improve physiological parameters which are of 21): 43–47). These are usually medicaments which have an importance in cases of an increased urge to urinate or urinary inhibiting action on the detrusor muscle,
Load more

Recommended publications
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • The Cardiovascular Actions of Mu and Kappa Opioid Agonists In
    THE CARDIOVASCULAR ACTIONS OF MU AND KAPPA OPIOID AGONISTS IN VIVO AND IN VITRO. By Abimbola T. Omoniyi, BSc (Hons) A thesis submitted in accordance with the requirements of the University of Surrey for the Degree of Doctor of Philosophy. Department of Pharmacology, September 1998. Cornell University Medical College, New York, NY 10021, ProQuest Number: 27733163 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 27733163 Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106 - 1346 ACKNOWLEDGEMENTS I would like to thank God through whom all things are made possible. Many thanks to Dr. Hazel Szeto for funding this thesis. Heartfelt gratitude to Dr. Dunli Wu for his support, encouragement and for keeping me sane. I thoroughly enjoyed the funny stories, the relentless Viagra jokes and endless tales of the Chinese revolution! Thanks to Dr. Yi Soong for all her support and generous assistance and all that food! Thanks to Dr. Ian Kitchen and Dr. Susanna Hourani for making this a successful collaborative degree. Thanks to my family for all their support and belief in me.
    [Show full text]
  • Misuse and Abuse of Opioid Analgesics – the Role of the Internet
    Misuse and Abuse of Opioid Analgesics – the Role of the Internet H. Siemann, J. Schnell, N. Scherbaum LVR Hospital Essen, Clinic for Dependent Behavior and Addiction Medicine University of Duisburg-Essen, Germany Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Opioid Analgesics • Prescription Drugs – Tramadol, Tilidine, Codeine, Loperamide – Easy to prescribe • Schedule III Drugs according to the German Narcotics Act (BtmG) – Morphine, Methadone, Fentanyl, Buprenorphine, Oxycodone – Special conditions to be fulfilled for a valid presciption Holger Siemann ([email protected]) 2 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Prescription Rate Holger Siemann ([email protected]) 3 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Non-Scheduled Opioids • Tramadol – Pain management (post-surgery treatment, injury treatment) • Tilidine + Naloxone (Valoron N®) – Higher analgesic potency – Prevention of parenteral drug abuse by combination with the µ-receptor antagonist Naloxone Holger Siemann ([email protected]) 4 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Aim of the Study • To assess the role of the internet regarding the abuse of prescription opioids – Role as a trading platform – Role as an information system Holger Siemann ([email protected]) 5 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Methods • Analysis of the first 50 websites provided by the leading search engine Google for
    [Show full text]
  • Table 6.12 Deaths from Poisoning, by Sex and Cause, Scotland, 2004
    Table 6.12 Deaths from poisoning, by sex and cause, Scotland, 2004 ICD Cause of death Both Males Females ICD Cause of death Both Males Females Codes and substance sexes Codes and substance sexes ACCIDENTS INTENTIONAL SELF-HARM X40 Accidental poisoning by and exposure X60 Intentional self-poisoning by -49 to noxious substances 57 40 17 -69 and exposure to 166 92 74 X40 Nonopioid analgesics, antipyretics X60 Nonopioid analgesics, antipyretics and antirheumatics and antirheumatics Ibuprofen 1 1 - Meptazinol, Alcohol 1 1 - Paracetamol 1 - 1 Meptazinol, Dihydrocodeine, Amitriptyline, Tramadol, Alcohol 1 1 - Imipramine, Alcohol 1 1 - Paracetamol 15 6 9 X41 Antiepileptic, sedative-hypnotic, Paracetamol, Codeine, Alcohol 1 1 - antiparkinsonism and Paracetamol, Diazepam 1 - 1 psychotropic drugs, Paracetamol, Oxazepam 1 1 - not elsewhere classified Tramadol 3 - 3 Clozapine, Diazepam, Alcohol 1 - 1 X61 Antiepileptic, sedative-hypnotic, antiparkinsonism and X42 Narcotics and psychodysleptics psychotropic drugs, (hallucinogens), not elsewhere not elsewhere classified classified Amitriptyline 8 3 5 Cocaine, Amphetamine 1 - 1 Amitriptyline, Alcohol 1 1 - Codeine, Tylex, Paracetamol, Alcohol 1 - 1 Amitriptyline, Dihydrocodeine 1 - 1 Dihydrocodeine, Diazepam 1 - 1 Amitriptyline, Paracetamol 1 1 - Ecstasy 1 1 - Carbamazepine 2 - 2 Heroin 4 3 1 Carbamazepine, Paroxetine, Paracetamol 1 1 - Heroin, Cocaine 1 1 - Chlordiazepoxide, Co-proxamol 1 - 1 Heroin, Methadone, Alcohol 1 1 - Chlorpromazine, Alcohol 2 2 - Heroin, Morphine 1 1 - Citalopram, Alcohol 1 -
    [Show full text]
  • Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)
    NATIONAL DEFENSE RESEARCH INSTITUTE Effects of Medication- Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes A Systematic Review Margaret A. Maglione, Laura Raaen, Christine Chen, Gulrez Shah Azhar, Nima Shahidinia, Mimi Shen, Ervant J. Maksabedian Hernandez, Roberta M. Shanman, Susanne Hempel Prepared for the Office of the Secretary of Defense Approved for public release; distribution unlimited For more information on this publication, visit www.rand.org/t/RR2108 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation R® is a registered trademark. Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Over the past two decades, the U.S. Department of Defense (DoD) has invested unparalleled resources into developing effective treatments for military-related psychological health conditions.
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • Guidelines for Prescribing Controlled Substances for Pain
    GUIDELINES FOR PRESCRIBI NG CONTROLLED SUBSTANCE S FOR PAIN MEDICAL BOARD OF CALIFORNIA NOVEMBER 2014 Edmund G. Brown Jr., Governor David Serrano Sewell, J.D., President, Medical Board of California Kimberly Kirchmeyer, Executive Director, Medical Board of California Guidelines for Prescribing Controlled Substances for Pain Table of Contents PREAMBLE ..................................................................................................................... 1 UNDERSTANDING PAIN ................................................................................................ 2 Pain ............................................................................................................................. 2 Acute and Chronic Pain ............................................................................................... 3 Nociceptive and Neuropathic Pain ............................................................................... 3 Cancer and Non-Cancer Pain ...................................................................................... 3 Tolerance, Dependence and Addiction ........................................................................ 4 Pain as an Illness......................................................................................................... 4 SPECIAL PATIENT POPULATIONS............................................................................... 4 Acute Pain ................................................................................................................... 4 Emergency
    [Show full text]
  • Double-Blind Crossover Trial of Oral Meptazinol, Pentazocine and Placebo in the Treatment of Pain in the Elderly V
    Postgrad Med J: first published as 10.1136/pgmj.56.657.474 on 1 July 1980. Downloaded from Postgraduate Medical Journal (July 1980) 56, 474-477 Double-blind crossover trial of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly V. PEARCE P. J. ROBSON M.B. B.S., M.R.C.P. M.B. B.S., M.R.C.P. Chesterton Hospital, Cambridge and Wyeth Laboratories, Maidenhead, Berkshire Summary unit, pentazocine 25 mg orally, and placebo. The 2 In a randomized, double-blind crossover trial in 30 active drugs were given in deliberately small doses elderly patients suffering from moderate to severe as it is well recognized that age is highly correlated pain, the analgesic efficacy, tendency to produce with the pain relief obtained from a given dose of mental confusion and side effect profile of meptazinol analgesic (Beliville et al., 1971) and that the elderly 100 mg orally were compared with those of pentazo- are more susceptible to drugs in general (Leading cine 25 mg orally and placebo. Article, 1977). Both the active drugs produced significantly better analgesia than placebo but meptazinol also provided Materials and methods significantly better pain relief than pentazocine, This was a randomized double-blind crossover whilst at the same time causing less mental confusion. trial in 30 patients over the age of 70 years who had Side effects were unremarkable. given informed consent to participate and whocopyright. Meptazinol appears to be a better general purpose would in any case have required a potent oral anal- oral analgesic in this group of patients than penta- gesic.
    [Show full text]
  • Guidelines for Pre Scribing Controlled Subs Tances for Pain
    GUIDELINES FOR PRE SCRIBING CONTROLLED SUBS TANCES FOR PAIN MEDICAL BOARD OF CALIFORNIA NOVEMBER 2014 Edmund G. Brown Jr., Governor David Serrano Sewell, J.D., President, Medical Board of California Kimberly Kirchmeyer, Executive Director, Medical Board of California Guidelines for Prescribing Controlled Substances for Pain Table of Contents PREAMBLE ..................................................................................................................... 1 UNDERSTANDING PAIN ................................................................................................ 2 Pain 2............................................................................................................................. Acute and Chronic Pain3 ............................................................................................... Nociceptive and Neuropathic Pain 3............................................................................... Cancer and Non-Cancer Pain ...................................................................................... 3 Tolerance, Dependence and Addiction 4........................................................................ Pain as an Illness.........................................................................................................4 SPECIAL PATIENT POPULATIONS...............................................................................4 Acute Pain 4................................................................................................................... Emergency Departments
    [Show full text]
  • 0 Cover Part Two\374
    PART TWO DEUXIÈME PARTIE SEGUNDA PARTE ﺍﳉﺰﺀ ﺍﻟﺜﺎﱐ 第二部分 ЧАСТЬ ВТΟΡАЯ - (...), [...] - (-)-3-hidroxi-N- (-)-(2R)-N-méthyl-1- fenacilmorfinán → Levophenacyl-morphan phénylpropan-2-amine → Levometamfetamine (-)-3-hidroxi-N- (-)-(3S,6R)-6- metilmorfinán → Levorphanol (dimethylamino)-4,4- (-)-3-hydroksymorfinan → Norlevorphanol diphenyl-3-heptanol → Betamethadol (-)-3-hydroksy-N- (-)-(3S,6R)-6- fenacylmorfinan → Levophenacyl-morphan (dimethylamino)-4,4- (-)-3-hydroksy-N- diphenyl-3-heptanol metylmorfinan → Levorphanol acetate (ester) → Betacetylmethadol (-)-3-hydroxymorphinan → Norlevorphanol (-)-(5R)-4,5-epoxy-3- (-)-3-hydroxy-N- methoxy-9α-methyl methylmorphinan → Levorphanol → Thebacon morphin-6-en-6-yl acetate (-)-3-hydroxynormorphinan → Norlevorphanol (-)-(5R,6S)-3-benzyloxy-4,5- (-)-3-hydroxy-N- epoxy-9a-methylmorphin- phenacylmorphinan → Levophenacyl-morphan 7-en-6-yl myristate → Myrophine (-)-3-hydroxytropane-2- (-)-(5R,6S)-4,5-epoxy carboxylat → Ecgonine morphin-7-en-3,6-diol → Normorphine (-)-3-idrossi-N- (-)-(5R,6S,14S)-4,5-epoxy- metilmorfinano → Levorphanol 14-hydroxy-3-methoxy- (-)-3-methoxy-N- 9a-methylmorphinan-6- methylmorphinan → Levomethorphan one → Oxycodone (-)-3-metil-2,2-difenil-4- (-)-(R)-4,5-epoxy-3- morfolinbutirilpirrolidina → Levomoramide methoxy-9a-methyl (-)-3-metoksy-N- morphinan-6-one → Hydrocodone metylmorfinan → Levomethorphan (-)-(R)-6-(dimethylamino)- (-)-3-metossi-N-metil- 4,4-diphenyl-3-heptanone → l-methadone morfinano → Levomethorphan (-)-(R)-N,α-dimethyl (-)-3-metoxi-N- phenethylamine → Levometamfetamine
    [Show full text]